Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic

References

• Sundar H, Fakhri B, Fayad LE, et al. NCCN guidelines version 1.2020 B-cell lymphomas NCCN evidence blocks TM continue NCCN guidelines panel disclosures ξ bone marrow transplantation ‡ hematology/hematology oncology Þ internal medicine † medical oncology ≠ pathology ¥ patient advocacy § radiotherapy/radiation oncology * Discussion writing committee member. 2020.
   Google Scholar
• Batlevi CL, Sha F, Alperovich A, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020;10(7):74. doi:10.1038/s41408-020-00340-z32678074
   PubMed Web of Science ®Google Scholar
• Ihle NT, Powis G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther. 2009;8(1):1–9. doi:10.1158/1535-7163.MCT-08-080119139107
   PubMed Web of Science ®Google Scholar
• Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008;27(41):5497–5510. doi:10.1038/onc.2008.24518794884
   PubMed Web of Science ®Google Scholar
• Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170(4):605–635. doi:10.1016/j.cell.2017.07.02928802037
   PubMed Web of Science ®Google Scholar
• Pongas G, Cheson BD. PI3K signaling pathway in normal B cells and indolent B-cell malignancies. Semin Oncol. 2016;43(6):647–654. doi:10.1053/j.seminoncol.2016.11.01128061982
   PubMed Web of Science ®Google Scholar
• Küppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5(4):251–262. doi:10.1038/nrc158915803153
   PubMed Web of Science ®Google Scholar
• Strout MP. Sugar-coated signaling in follicular lymphoma. Blood. 2015;126(16):1871–1872. doi:10.1182/blood-2015-08-66514126472734
   PubMed Web of Science ®Google Scholar
• Amin R, Mourcin F, Uhel F, et al. DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma. Blood. 2015;126(16):1911–1920. doi:10.1182/blood-2015-04-64091226272216
   PubMed Web of Science ®Google Scholar
• Linley A, Krysov S, Ponzoni M, Johnson PW, Packham G, Stevenson FK. Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells. Blood. 2015;126(16):1902–1910. doi:10.1182/blood-2015-04-64080526194765
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Cheson BD. How we manage follicular lymphoma. Leukemia. 2014;28(7):1388–1395. doi:10.1038/leu.2014.9124577532
   PubMed Web of Science ®Google Scholar
• Leseux L, Hamdi SM, Al Saati T, et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood. 2006;108(13):4156–4162. doi:10.1182/blood-2006-05-02620316912221
   PubMed Web of Science ®Google Scholar
• Mourcin F, Pangault C, Amin-Ali R, Amé-Thomas P, Tarte K. Stromal cell contribution to human follicular lymphoma pathogenesis. Front Immunol. 2012;3(SEP). doi:10.3389/fimmu.2012.00280
   PubMed Web of Science ®Google Scholar
• Dil N, Marshall AJ. Role of phosphoinositide 3-kinase p110δ in TLR4- and TLR9-mediated B cell cytokine production and differentiation. Mol Immunol. 2009;46(10):1970–1978. doi:10.1016/j.molimm.2009.03.01019362372
   PubMed Web of Science ®Google Scholar
• Guo H, Samarakoon A, Vanhaesebroeck B, Malarkannan S. The p110δ of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation. J Exp Med. 2008;205(10):2419–2435. doi:10.1084/jem.2007232718809712
   PubMed Web of Science ®Google Scholar
• Herman SEM, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116(12):2078–2088. doi:10.1182/blood-2010-02-27117120522708
   PubMed Web of Science ®Google Scholar
• Krause G, Hassenrück F, Hallek M. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. Drug Des Devel Ther. 2018;12:2577–2590. doi:10.2147/DDDT.S142406
   PubMed Web of Science ®Google Scholar
• Dong T, Liu Z, Zhao S, et al. The expression of CD9 and PIK3CD is associated with prognosis of follicular lymphoma. J Cancer. 2015;6(12):1222–1229. doi:10.7150/jca.1127926535063
   PubMed Web of Science ®Google Scholar
• Yang Q, Modi P, Newcomb T, Quéva C, Gandhi V. Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin Cancer Res. 2015;21(7):1537–1542. doi:10.1158/1078-0432.CCR-14-203425670221
   PubMed Web of Science ®Google Scholar
• Bird ST, Tian F, Flowers N, et al. Idelalisib for treatment of relapsed follicular lymphoma and chronic lymphocytic leukemia: a comparison of treatment outcomes in clinical trial participants vs medicare beneficiaries. JAMA Oncol. 2020;6(2):248–254. doi:10.1001/jamaoncol.2019.399431855259
   PubMed Web of Science ®Google Scholar
• Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO: a Phase II study of duvelisib (IPI-145) in patients with refractory indolent non-hodgkin lymphoma. J Clin Oncol. 2019;37(11):912–922. doi:10.1200/JCO.18.0091530742566
   PubMed Web of Science ®Google Scholar
• Liu N, Rowley BR, Bull CO, et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. Mol Cancer Ther. 2013;12(11):2319–2330. doi:10.1158/1535-7163.MCT-12-0993-T24170767
   PubMed Web of Science ®Google Scholar
• Fda, Cder. Highlights of prescribing information. [cited 712, 2020]. Available from: www.fda.gov/medwatch.
   Google Scholar
• Gerisch M,  Schwarz T,  Lang D, et al. Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [14 C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers. Cancer Chemother Pharmacol. 2017 Sep;80(3):535–544. doi:10.1007/s00280-017-3383-9
   Google Scholar
• Paul J, Soujon M, Wengner AM, et al. Simultaneous inhibition of PI3Kδ and PI3Kα induces ABC-DLBCL regression by blocking BCR-dependent and -independent activation of NF-κB and AKT. Cancer Cell. 2017;31(1):64–78. doi:10.1016/j.ccell.2016.12.00328073005
   PubMed Web of Science ®Google Scholar
• Patnaik A, Appleman LJ, Tolcher AW, et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin’s lymphomas. Ann Oncol. 2016;27(10):1928–1940. doi:10.1093/annonc/mdw28227672108
   PubMed Web of Science ®Google Scholar
• Doi T, Fuse N, Yoshino T, et al. A phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors. Cancer Chemother Pharmacol. 2017;79(1):89–98. doi:10.1007/s00280-016-3198-027915408
   PubMed Web of Science ®Google Scholar
• Shapiro GI, Bell-McGuinn KM, Molina JR, et al. First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer. Clin Cancer Res. 2015;21(8):1888–1895. doi:10.1158/1078-0432.CCR-14-130625652454
   PubMed Web of Science ®Google Scholar
• Dreyling M, Morschhauser F, Bouabdallah K, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28:2169–2178. doi:10.1093/annonc/mdx28928633365
   PubMed Web of Science ®Google Scholar
• Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014;123(22):3406–3413. doi:10.1182/blood-2013-11-53854624615776
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–1018. doi:10.1056/NEJMoa131458324450858
   PubMed Web of Science ®Google Scholar
• Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by Copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35(35):3898–3905. doi:10.1200/JCO.2017.75.464828976790
   PubMed Web of Science ®Google Scholar
• Dreyling M, Santoro A, Mollica L, et al. Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study. Am J Hematol. 2020;95(4):ajh.25711. doi:10.1002/ajh.25711
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Gorbatchevsky I, Hiemeyer F, Cupit L, Childs BH. Abstract CT212: CHRONOS-2: a randomized, double-blind phase III study of phosphatidylinositol-3 kinase alpha/delta inhibitor copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin’s lymphoma (iNHL). Cancer Res. 2015;CT212–CT212.
   Web of Science ®Google Scholar
• Cheson BD, O’brien S, Ewer MS, et al. Optimal management of adverse events from copanlisib in the treatment of patients with non-hodgkin lymphomas. Clin Lymphoma Myeloma Leuk. 2019;19(3):135–176. doi:10.1016/j.clml.2018.11.02130584024
   PubMed Web of Science ®Google Scholar
• Hanker AB, Kaklamani V, Arteaga CL. Challenges for the clinical development of PI3K inhibitors: strategies to improve their impact in solid tumors. Cancer Discov. 2019;9(4):482–491. doi:10.1158/2159-8290.CD-18-117530867161
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Santoro A, Mollica L, et al. Copanlisib, a PI3K inhibitor, demonstrates a favorable long-term safety profile in a pooled analysis of patients with hematologic malignancies. Blood. 2019;134(Supplement_1):4009. doi:10.1182/blood-2019-131779
   Web of Science ®Google Scholar
• Morschhauser F, Machiels JP, Salles G, et al. On-target pharmacodynamic activity of the PI3K inhibitor copanlisib in paired biopsies from patients with malignant lymphoma and advanced solid tumors. Mol Cancer Ther. 2020;19(2):468–478. doi:10.1158/1535-7163.MCT-19-046631619463
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Santoro A, Mollica L, et al. Outcomes for patients with pre-existing diabetes or hypertension treated with copanlisib from the CHRONOS-1 study in patients with relapsed or refractory indolent B-cell lymphoma. Blood. 2018;132(Supplement1):1613. doi:10.1182/blood-2018-99-117063
   Web of Science ®Google Scholar
• Hopkins BD, Pauli C, Xing D, et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018;560(7719):499–503. doi:10.1038/s41586-018-0343-430051890
   PubMed Web of Science ®Google Scholar
• Busaidy NL, Farooki A, Dowlati A, et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol. 2012;30(23):2919–2928. doi:10.1200/JCO.2011.39.735622778315
   PubMed Web of Science ®Google Scholar
• Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study. J Clin Oncol. 2015;33(23):2516–2522. doi:10.1200/JCO.2014.59.753426124482
   PubMed Web of Science ®Google Scholar
• Lansigan F, Barak I, Pitcher B, et al. The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: a combined analysis of 3 CALGB trials. Cancer Med. 2019;8(1):165–173. doi:10.1002/cam4.191830575311
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, Flowers C, et al. Activity of idelalisib in high-risk follicular lymphoma with early relapse following front line immunochemotherapy. Blood. 2015;126(23):2744. doi:10.1182/blood.V126.23.2744.2744
   Web of Science ®Google Scholar
• Dreyling M, Santoro A, Leppä S, et al. Efficacy and safety in high-risk relapsed or refractory indolent follicular lymphoma patients treated with copanlisib. Hematol Oncol. 2019;37:387–389. doi:10.1002/hon.57_2631
   Google Scholar
• Cheah CY, Fowler NH. Idelalisib in the management of lymphoma. Blood. 2016;128(3):331–336. doi:10.1182/blood-2016-02-70276127252232
   PubMed Web of Science ®Google Scholar
• Iyengar S, Clear A, Bödör C, et al. P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood. 2013;121(12):2274–2284. doi:10.1182/blood-2012-10-46083223341541
   PubMed Web of Science ®Google Scholar
• Sorensen R, Meadows S, Yahiaoui A, et al. Investigation of the mechanism of idelalisib resistance in the follicular lymphoma WSU-Fsccl cell line. Blood. 2015;126(23):2482. doi:10.1182/blood.V126.23.2482.2482
   Web of Science ®Google Scholar
• Appukkuttan S, Duchesneau E, Zichlin ML, et al. A budget impact analysis of the introduction of copanlisib for treatment of relapsed follicular lymphoma in the United States. J Manag Care Spec Pharm. 2019;25(4):437–446. doi:10.18553/jmcp.2019.18259
   PubMed Web of Science ®Google Scholar
• Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–1265. doi:10.1182/blood-2003-12-443415126323
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555–4562. doi:10.1200/JCO.2008.21.399119652063
   PubMed Web of Science ®Google Scholar
• Vindi J, Kridel R, Staiger AM, et al. A clinicogenetic risk model (m7-FLIPI) prospectively identifies one-half of patients with early disease progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2015;126(23):333. doi:10.1182/blood.V126.23.333.333
   Web of Science ®Google Scholar
• Huet S, Tesson B, Jais JP, et al. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol. 2018;19(4):549–561. doi:10.1016/S1470-2045(18)30102-529475724
   PubMed Web of Science ®Google Scholar
• Lockmer S, Ren W, Brodtkorb M, et al. M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy. Br J Haematol. 2020;188(2):259–267. doi:10.1111/bjh.1615931423576
   PubMed Web of Science ®Google Scholar
• Nastoupil LJ, Flowers CR, Leonard JP. Sequencing of therapies in relapsed follicular lymphoma. Hematol. 2018;2018(1):189–193.
   PubMedGoogle Scholar
• Hirayama AV, Gauthier J, Hay KA, et al. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood. 2019;134(7):636–640. doi:10.1182/blood.201900090531648294
   PubMed Web of Science ®Google Scholar
• Modi P, Balakrishnan K, Yang Q, Wierda WG, Keating MJ, Gandhi V. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells. Oncotarget. 2017;8(10):16259–16274. doi:10.18632/oncotarget.1518028187444
   PubMedGoogle Scholar
• Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase ib study. J Clin Oncol. 2016;34(23):2698–2704. doi:10.1200/JCO.2015.65.978927269947
   PubMed Web of Science ®Google Scholar
• Ali K, Soond DR, Piñeiro R, et al. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014;510(7505):407–411. doi:10.1038/nature1344424919154
   PubMed Web of Science ®Google Scholar
• Pachter JA, Weaver DT. The dual PI3K-δ,γ inhibitor duvelisib stimulates anti-tumor immunity and enhances efficacy of immune checkpoint and co-stimulatory antibodies in a B cell lymphoma model. Blood. 2017;130(Supplement1):1541.
   Google Scholar
• Coyne GO, Yap TA, Moore N, et al. Abstract B105: phase IB combination study of copanlisib and nivolumab in advanced solid tumors and lymphomas. Mol Cancer Ther. 2019;B105–B105.
   Web of Science ®Google Scholar
• Smith SM, Pitcher BN, Jung SH, et al. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for clinical trials in oncology A051201 and A051202 phase 1 trials. Lancet Haematol. 2017;4(4):e176–82. doi:10.1016/S2352-3026(17)30028-528314699
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Barrientos JC, Brown JR, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017;18(3):297–311.28139405
   PubMed Web of Science ®Google Scholar
• Barr PM, Saylors GB, Spurgeon SE, et al. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood. 2016;127(20):2411–2415. doi:10.1182/blood-2015-12-68351626968534
   PubMed Web of Science ®Google Scholar
• Choudhary GS, Al-Harbi S, Mazumder S, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015;6(1):e1593. doi:10.1038/cddis.2014.52525590803
   PubMed Web of Science ®Google Scholar
• Tarantelli C, Lange M, Gaudio E, et al. Copanlisib synergizes with conventional and targeted agents including venetoclax in B- And T-cell lymphoma models. Blood Adv. 2020;4(5):819–829. doi:10.1182/bloodadvances.201900084432126142
   PubMed Web of Science ®Google Scholar
• Burris HA, Flinn IW, Patel MR, et al. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018;19(4):486–496. doi:10.1016/S1470-2045(18)30082-229475723
   PubMed Web of Science ®Google Scholar
• Davids M, Flinn I, Mato A. Long term integrated safety analysis of umbralisib (TGR-1202), a PI3K-delta/CK1-epsilon inhibitor with a differentiated safety profile, in patients with relapsed/refractory lymphoid malignancies. 2018 cited 101, 2020]. Available from: https://library.ehaweb.org/eha/2018/stockholm/214906/matthew.s.davids.md.mmsc.long.term.integrated.safety.analysis.of.umbralisib.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dunity.
   Google Scholar
• Zelenetz AD, Reddy N, Jagadeesh D, et al. Tolerability and durable response of the PI3Kδ inhibitor ME-401 administered on an intermittent schedule in relapsed/refractory (R/R) follicular lymphoma (FL) and other B-cell malignancies. J Clin Oncol. 2020;38(15_suppl):8016. doi:10.1200/JCO.2020.38.15_suppl.8016
   Web of Science ®Google Scholar
• Zelenetz AD, Jagadeesh D, Reddy NM, et al. Results of the PI3Kδ inhibitor ME-401 alone or with rituximab in relapsed/refractory (R/R) follicular lymphoma (FL). J Clin Oncol. 2019;37(15_suppl):7512. doi:10.1200/JCO.2019.37.15_suppl.7512
   Web of Science ®Google Scholar